ACCESS HCM: Real World Evidence for Artificial-Intelligence-assisted Screening and Access to Care for HCM - A Multi-Site Registry

Status: Recruiting

Location: See all (3) locations...

Intervention Type: Device

Study Type: Observational

SUMMARY

To describe the clinical, economic, and population characteristics of newly diagnosed, previously diagnosed, and suspected patients evaluated by Viz HCM. HCM is underdiagnosed in the community and AI algorithms have been developed as screening tools. However, it is not well understood how to best integrate AI screening tools and their potential impact.

Eligibility

Participation Requirements

Sex: All

Minimum Age: 18

Healthy Volunteers: f

View:

⁃ All Cohorts

• Patients aged 18+ years at time of arrival to healthcare facility

• Patients with a resting 12-lead digital electrocardiogram (ECG) that is flagged by Viz HCM for HCM suspicion

⁃ Additional cohort-specific criteria:

⁃ Cohort 1 - Newly Diagnosed Patients

• Patients have been diagnosed with HCM after the Viz HCM implementation

• Written informed consent is obtained prior to data collection

⁃ Cohort 2 - Previously Diagnosed Patients ● Prior diagnosis of HCM as evidenced by clinical diagnosis documentation prior to Viz HCM implementation

⁃ Cohort 3 - Suspected and Not Diagnosed Patients

⁃ ● Patients did not receive sufficient clinical workup for HCM diagnosis confirmation

⁃ Cohort 4 - Unlikely HCM ● Patient ECG moved to 'Unlikely HCM' group within Viz by site study staff following HCM alert review

⁃ Cohort 5 - Alerts Not Reviewed

⁃ ● HCM alert not reviewed by site study staff during study enrollment period

Locations

United States

Georgia

Emory University

NOT_YET_RECRUITING

Atlanta

Illinois

North Shore University Health System

RECRUITING

Evanston

Pennsylvania

Thomas Jefferson University

RECRUITING

Philadelphia

Contact Information

Primary

Sloane Smith-Saunders, MBA, MPH

sloane.smith-saunders@viz.ai

‪(754) 307-6336‬

Backup

Ethan Carter, BSN

ethan.carter@viz.ai

‪(415) 409-9369‬

Time Frame

Start Date: 2025-06-13

Estimated Completion Date: 2028-12

Participants

Target number of participants: 500

Treatments

Cohort 1- Newly Diagnosed Patients

This cohort will consist of individuals who are newly diagnosed with HCM after the site began using Viz HCM. These patients will serve as a key population to assess the AI tool's impact on diagnoses, timeliness, and subsequent initiation of treatment. Data collected will include pre-diagnostic clinical indicators, diagnostic pathways, and treatment decisions following diagnosis. This cohort will begin to describe patient access to care and the clinical outcomes following a new HCM diagnosis in an AI-augmented clinical workflow.

Cohort 2 - Previously Diagnosed Patients

Patients in this cohort will have an existing diagnosis of HCM prior to the start of using Viz HCM. This group will allow for the evaluation of how the AI tool may influence ongoing management strategies, such as treatment adjustments, monitoring practices, risk stratification, and clinical outcomes. The cohort will also help assess whether the AI tool facilitates optimization of care by identifying missed opportunities or previously unrecognized complications.

Cohort 3 - Suspected and Not Diagnosed Patients

This cohort will include patients who were suspected by Viz HCM users of having underlying HCM, but clinical work-up sufficient to produce a diagnosis of HCM (including imaging and/or genetic testing) did not occur within the data collection period. Data collected will focus on diagnostic pathways, attempts made to coordinate care, and categorical barriers to care.

Cohort 4 - Unlikely HCM

This cohort will look at a subset of randomly selected patients who are suspected by Viz HCM of having underlying HCM but are moved to the subgroup 'Unlikely HCM' within the Viz app/web by a clinician. After 1 year of study enrollment, a list will be created by Viz and shared with study teams for collection of additional minimal data including age, sex, reason for unlikely HCM (via chat), demographics (race, ethnicity) and reason for ECG.

Cohort 5 - Alerts Not Reviewed

This cohort will look at a subset of randomly selected patients who are suspected by Viz HCM of having underlying HCM, but the alert is never reviewed by a clinician. After 1 year of study enrollment, a list will be created by Viz and shared with study teams for collection of additional minimal data including age, sex, demographics (race, ethnicity) and reason for ECG.

Related Therapeutic Areas

Cardiomyopathy

Hypertrophic Cardiomyopathy (HCM)

Similar Clinical Trials

View All

ACCESS HCM: Real World Evidence for Artificial-Intelligence-assisted Screening and Access to Care for HCM - A Multi-Site Registry

Similar Clinical Trials

The EXerCise traIning To rEcovery in HCM Trial

The EXerCise traIning To rEcovery in HCM Trial

Prospective Evaluation of Artificial Intelligence ECG With Consumer-Facing ECG Devices for Detection of Hypertrophic Cardiomyopathy and Distinction From Athlete's

Prospective Evaluation of Artificial Intelligence ECG With Consumer-Facing ECG Devices for Detection of Hypertrophic Cardiomyopathy and Distinction From Athlete's

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of SOtaglifloziN in symptomATic Obstructive And Non-obstructive Hypertrophic CardioMyopathy (SONATA-HCM)

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of SOtaglifloziN in symptomATic Obstructive And Non-obstructive Hypertrophic CardioMyopathy (SONATA-HCM)